I
Ianthus Capital Holdings Inc
CNSX:IAN
Ianthus Capital Holdings Inc
CNSX:IAN
Price:
0.005
CAD
Market Closed
Market Cap:
CA$34.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Ianthus Capital Holdings Inc
CNSX:IAN
|
CA |
|
J
|
JTF International Holdings Ltd
HKEX:8479
|
CN |
Multiples-Based Value
The Multiples-Based Value of one IAN stock under the Base Case scenario is 0.03 CAD. Compared to the current market price of 0.005 CAD, Ianthus Capital Holdings Inc is Undervalued by 83%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IAN
Multiples-Based Value
Base Case
0.03
CAD
Undervaluation 83%
I
Multiples Across Competitors
IAN Competitors Multiples
Ianthus Capital Holdings Inc Competitors
Ianthus Capital Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
I
|
Ianthus Capital Holdings Inc
CNSX:IAN
|
34.1m CAD | 0.2 | 14.8 | 31.5 | -13.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879.7B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.2 | 11.4 | 12.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.4 | 30.9 | 17.1 | 24 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.2 | 20.9 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.6 | 7.8 | 9.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.4 | 16.5 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
